Pharmacovigilance inspections are not rare events to be prepared for once. Guidance expects marketing authorisation holders to be inspected at least once every four years, and to be inspection-ready at all times, because inspections may be unannounced. The published findings show where the pressure actually falls — and it is not where most companies rehearse.
The legal footing
Article 111 of Directive 2001/83/EC gives national competent authorities, in cooperation with EMA, the power to inspect the premises, records, documents and pharmacovigilance system master file of the holder or any firm employed by the holder to perform pharmacovigilance activities. That last clause is the one that reaches your service providers. Article 19 of Regulation (EC) No 726/2004 makes the supervisory authority responsible for verifying, on behalf of the Union, that the holder satisfies its Title IX obligations, and allows pre-authorisation inspections to check that the system described in the application actually exists.
For centrally authorised products the supervisory authority is the competent authority of the Member State where the PSMF is located. EMA coordinates; CHMP adopts the risk-based programme and PRAC recommends “for cause” inspections. Guidance on Good Pharmacovigilance Practices Module III sets the framework, distinguishing system from product-related inspections, routine from for-cause, announced from unannounced, and providing for re-inspections and remote inspections.
How findings are graded
The Union procedures classify findings on a three-point scale:
- Critical — a deficiency that adversely affects the rights, safety or well-being of patients, poses a potential risk to public health, or represents a serious violation of legislation and guidelines.
- Major — a deficiency that could potentially have those effects, or represents a violation of legislation and guidelines.
- Minor — a deficiency not expected to adversely affect patients.
Outcomes are not confined to the inspecting authority. Inspection information is shared through a common repository accessible to Member States, EMA and the Commission, and EMA maintains an EU list of planned and conducted pharmacovigilance inspections, updated by national authorities at least quarterly and circulated to PRAC. Where findings are critical or major, the report or an English summary must be shared, together with CAPA status.
What the 2024 inspections actually found
EMA’s annual report of the Pharmacovigilance Inspectors’ Working Group for 2024 is the only published breakdown, and it is worth reading rather than paraphrasing. Fifty-nine human pharmacovigilance inspections were conducted under the centralised programme — ten requested by CHMP and 49 under national programmes — with 52 at the QPPV or PSMF site.
Across the ten CHMP-requested inspections, 87 deficiencies were recorded: no critical findings, 29 major (33%) and 58 minor (67%). The three areas attracting most findings were:
- Management and reporting of adverse reactions — 22 findings, twelve of them major, concentrated on submission and follow-up processes, medical review and MedDRA coding, literature screening, and receipt and collation of individual case safety reports from all sources at a single collection point within the EU.
- The quality management system.
- The pharmacovigilance system master file.
Note what this pattern implies. Zero critical findings suggests systems are broadly sound; a third of findings graded major suggests the problems are in execution and documentation of routine processes, not in system design.
Timelines you should plan against
For routine national inspections, guidance treats six to eight weeks as sufficient notice, though authorities may inspect at any time and national procedures vary. For CHMP-requested inspections, indicative timings run from announcement within about ten days of the CHMP decision, through preparation and conduct, to an inspection report issued within around 30 working days of the end of the inspection. The holder is then expected to provide its CAPA plan within 30 working days of receiving the report — an absence of reply is itself recorded.
Separately, the PSMF must be made available no later than seven calendar days after a request, and pharmacovigilance data must be accessible from at least one point in the Union.
Consequences
Commission Regulation (EC) No 658/2007 provides for fines of up to 5% of the holder’s Union turnover in the preceding business year, with daily periodic penalty payments of up to 2.5% of average daily Union turnover where the infringement continues, and up to 0.5% for non-cooperation. Non-financial consequences range from warning letters and publication of non-compliance to urgent safety restrictions, variation, suspension or revocation of the authorisation.
A Greek note
EOF publishes no dedicated pharmacovigilance inspection circular or procedure — its published inspection guidance covers GMP, GLP, manufacturing, import and wholesale. Greek holders are inspected under the general EU framework. What Greece does add is a mandatory national pharmacovigilance contact person, with specified qualifications, reporting to the EU QPPV.
How PQRA helps
We run mock pharmacovigilance inspections against the areas the published findings actually target, audit the PSMF for accuracy against practice rather than against its own last revision, review case management, literature screening and single-point ICSR collation, audit service providers and licensing partners under the same standard an inspector would apply, and draft and track CAPA responses inside the 30-working-day window.
Due an inspection, or unsure when you last were? Ask PQRA for a readiness assessment.
No responses yet